OSNER ETIENNE: Open Payments
NPI 1942807367 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,758 in 231 payments from 20 companies in 2025. Trend: 2023 $3,859 · 2024 $3,824 · 2025 $4,758
Food & beverage: $4,758
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $650 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $527 |
| Otsuka America Pharmaceutical, Inc. | 17 | $412 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $360 |
| Axsome Therapeutics, Inc. | 18 | $352 |
| Teva Pharmaceuticals USA, Inc. | 29 | $347 |
| Alkermes, Inc. | 16 | $330 |
| ABBVIE INC. | 18 | $317 |
| Vanda Pharmaceuticals Inc. | 10 | $272 |
| Bausch Health US, LLC | 10 | $231 |
Products named: INGREZZA, CAPLYTA, REXULTI, TRINTELLIX, Auvelity, VRAYLAR, ARISTADA, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
